The invention belongs to the technical field of bioengineering, and relates to an
analysis method for expression and
immunogenicity of recombinant
human rotavirus VP7
protein. The method comprises the following steps: firstly, designing a primer according to a VP7
complete sequence (NC007571.1) published in GeneBank, carrying out
nucleic acid extraction on a
disease material, carrying out reverse transcription on cDNA (
complementary deoxyribonucleic acid) as a template,
cloning a VP7
gene, constructing an
expression vector pESP-2-VP7, and transforming
schizosaccharomyces pombe; vP7 expression is induced by 1% IPTG (
isopropyl-beta-d-thiogalactoside), separation and purification are performed to obtain the VP7
protein, and mice are immunized by the VP7
protein in different immunization
modes to evaluate the
immune protection effect of the VP7 protein. The results show that the primer design is consistent with the prediction result, the length of the cloned VP7
gene is 1050 bp, and the SDS-PAGE and
Western Blot identification results show that the protein size is 63 kDa; after a mouse is immunized by the VP7 protein, IgG, SIgA and
neutralizing antibody results show that the immune effect of 50 micrograms of each nasal drop is better than that of 20 micrograms of each nasal drop and an injection group (50, 20 micrograms of each nasal drop); and the nasal drop
immunity has a relatively high challenge protection rate of 100%.